Evidence map›Paper›PMID 34951138›Full record

ArticleJournal of cachexia, sarcopenia and muscle2022

Ovarian cancer ascites induces skeletal muscle wasting in vitro and reflects sarcopenia in patients.

Jorne Ubachs, Wouter R P H van de Worp, Rianne D W Vaes, Kenneth Pasmans, Ramon C Langen, Ruth C R Meex, Annemarie A J H M van Bijnen, Sandrina Lambrechts, Toon Van Gorp, Roy F P M Kruitwagen and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Interpretable machine learning model based on clinical factors for predicting muscle radiodensity loss after treatment in ovarian cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Association of prognostic nutritional index with muscle loss and survival in patients with ovarian cancer treated with primary debulking surgery and chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Jorne UbachsDepartment of Obstetrics and Gynecology, Maastricht University Medical Centre, Maastricht, The Netherlands.ORCID 0000-0001-9498-6162
Wouter R P H van de WorpNUTRIM, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands.
Rianne D W VaesDepartment of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.
Kenneth PasmansNUTRIM, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands.
Ramon C LangenNUTRIM, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands.
Ruth C R MeexNUTRIM, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands.
Annemarie A J H M van BijnenDepartment of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.
Sandrina LambrechtsDepartment of Obstetrics and Gynecology, Maastricht University Medical Centre, Maastricht, The Netherlands.
Toon Van GorpDepartment of Obstetrics and Gynecology, Division of Gynecological Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.
Roy F P M KruitwagenDepartment of Obstetrics and Gynecology, Maastricht University Medical Centre, Maastricht, The Netherlands.
Steven W M Olde DaminkDepartment of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.
Sander S RensenDepartment of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.
Maastricht University Medical Centre · NLMaastricht University · NLVIB-KU Leuven Center for Cancer Biology · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCachexia-associated skeletal muscle wasting or 'sarcopenia' is highly prevalent in ovarian cancer and contributes to poor outcome. Drivers of cachexia-associated sarcopenia in ovarian cancer remain elusive, underscoring the need for novel and better models to identify tumour factors inducing sarcopenia. We aimed to assess whether factors present in ascites of sarcopenic vs. non-sarcopenic ovarian cancer patients differentially affect protein metabolism in skeletal muscle cells and to determine if these effects are correlated to cachexia-related patient characteristics.

methodsFifteen patients with an ovarian mass and ascites underwent extensive physical screening focusing on cachexia-related parameters. Based on computed tomography-based body composition imaging, six cancer patients were classified as sarcopenic and six were not; three patients with a benign condition served as an additional non-sarcopenic control group. Ascites was collected, and concentrations of cachexia-associated factors were assessed by enzyme-linked immunosorbent assay. Subsequently, ascites was used for in vitro exposure of C2C12 myotubes followed by measurements of protein synthesis and breakdown by radioactive isotope tracing, qPCR-based analysis of atrophy-related gene expression, and NF-κB activity reporter assays.

resultsC2C12 protein synthesis was lower after exposure to ascites from sarcopenic patients (sarcopenia 3.1 ± 0.1 nmol/h/mg protein vs. non-sarcopenia 5.5 ± 0.2 nmol/h/mg protein, P < 0.01), and protein breakdown rates tended to be higher (sarcopenia 31.2 ± 5.2% vs. non-sarcopenia 20.9 ± 1.9%, P = 0.08). Ascites did not affect MuRF1, Atrogin-1, or REDD1 expression of C2C12 myotubes, but NF-κB activity was specifically increased in cells exposed to ascites from sarcopenic patients (sarcopenia 2.2 ± 0.4-fold compared with control vs. non-sarcopenia 1.2 ± 0.2-fold compared with control, P = 0.01). Protein synthesis and breakdown correlated with NF-κB activity (r

conclusionsAscites of sarcopenic ovarian cancer patients induces pronounced skeletal muscle protein metabolism changes in C2C12 cells that correlate with clinical muscle measures of the patient and that are characteristic of cachexia. The use of ascites offers a new experimental tool to study the impact of both tumour-derived and systemic factors in various cachexia model systems, enabling identification of novel drivers of tissue wasting in ovarian cancer.

Indexed as

Ovarian NeoplasmsSarcopeniaAscitesCachexiaHumansMuscle, SkeletalAtrogenesC2C12 cellsInterleukin-6MyotubesNF-κBProtein breakdownProtein synthesisTranslational research

Identifiers

PMID34951138
PMCPMC8818657
OpenAlexW4200132179

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.